The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
|Articles|September 14, 2005
Delayed Development of Keloid in Pierced Ear
Author(s)Robert L. Soley, MD
Twelve years after having her ear pierced, a 58-year-old woman presented with a keloid on the right lobe's medial surface.
Advertisement
Twelve years after having her ear pierced, a 58-year-old woman presented with a keloid on the right lobe's medial surface. The lesion initially developed 2 years after the piercing, at which time it was excised and intralesional triamcinolone acetonide was administered intermittently. The keloid recurred 2 years later.
The patient sought treatment of the recurrent keloid 8 years later. The lesion was excised and a 2-year regimen of intralesional triamcinolone acetonide-given every 3 months-was begun.
Advertisement
Related to this article
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata
2
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
3
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
4
ACCORD Trials: Efficacy and Safety of Dextromethorphan-Bupropion in Agitation
5